With this analysis,BRAFhad a prognostic rather than a predictive impact
With this analysis,BRAFhad a prognostic rather than a predictive impact. summarized. Even though discovery ofKRASmutations offers improved patient selection for EGFR-targeted treatments, further biomarkers are required, especially for those individuals who exhibitKRASmutations rather than the wild-type gene. Keywords:EGFR, colorectal malignancy, predictive biomarker, KRAS == Intro == The arrival of targeted therapies for colorectal malignancy (CRC) has brought the potential to prescribe therapy for the specific abnormalities within an individual tumor and hence personalize treatment. Although discoveries such asKRASgene mutations have made inroads into this field, we have not yet recognized the full potential of targeted therapies. Several factors are required for the personalization of treatment, including recognition of the aberrant Xanthopterin (hydrate) pathway/s involved and the development of drugs to target these specific pathways, in order to select the right…